INT137528

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.20
First Reported 2006
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 0.46
Pain Relevance 2.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CD177)
Anatomy Link Frequency
BFA 1
CD177 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 13 99.08 Very High Very High Very High
Immobilon 2 96.80 Very High Very High Very High
fortral 2 96.20 Very High Very High Very High
Potency 3 90.00 High High
Pain 6 85.72 High High
narcan 4 85.36 High High
tetrodotoxin 12 83.84 Quite High
Kappa opioid receptor 2 75.00 Quite High
antagonist 4 73.44 Quite High
abdominal pain 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Intussusception 80 91.76 High High
Pain 3 85.72 High High
Gastroenteritis 8 5.00 Very Low Very Low Very Low
Disease 7 5.00 Very Low Very Low Very Low
Immunization 3 5.00 Very Low Very Low Very Low
Diarrhoea 2 5.00 Very Low Very Low Very Low
Vomiting 2 5.00 Very Low Very Low Very Low
Fever 2 5.00 Very Low Very Low Very Low
Death 1 5.00 Very Low Very Low Very Low
Emergencies 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
000 recipients of PRV, a remarkably large number.
Negative_regulation (recipients) of PRV
1) Confidence 0.20 Published 2008 Journal Clinical Trials (London, England) Section Body Doc Link PMC2602609 Disease Relevance 0.23 Pain Relevance 0
BFA treatment enhanced down-regulation of the cell surface receptor induced by nonpeptide agonists, but not that by peptide agonists, and unmasked etorphine- and pentazocine-mediated receptor down-regulation.
Negative_regulation (down-regulation) of cell surface receptor in BFA associated with fortral, agonist and immobilon
2) Confidence 0.18 Published 2006 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 16882876 Disease Relevance 0 Pain Relevance 0.85
Ranolazine caused a preferential hyperpolarizing shift of the steady-state fast, intermediate and slow inactivation of hNa(V)1.7 and intermediate and slow inactivation of rNa(V)1.8, suggesting preferential interaction of the drug with the inactivated states of both channels.
Negative_regulation (inactivation) of hNa
3) Confidence 0.00 Published 2008 Journal Channels (Austin) Section Abstract Doc Link 19077543 Disease Relevance 0.07 Pain Relevance 0.40
Ranolazine caused a preferential hyperpolarizing shift of the steady-state fast, intermediate and slow inactivation of hNa(V)1.7 and intermediate and slow inactivation of rNa(V)1.8, suggesting preferential interaction of the drug with the inactivated states of both channels.
Negative_regulation (inactivation) of hNa
4) Confidence 0.00 Published 2008 Journal Channels (Austin) Section Abstract Doc Link 19077543 Disease Relevance 0.07 Pain Relevance 0.40
Ranolazine reduced hNa(V)1.7 and rNa(V)1.8 I(Na) with IC50 values of 10.3 and 21.5 microM (holding potential = -120 or -100 mV, respectively).
Negative_regulation (reduced) of hNa
5) Confidence 0.00 Published 2008 Journal Channels (Austin) Section Abstract Doc Link 19077543 Disease Relevance 0.09 Pain Relevance 0.45

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox